5-thioxo-4,5-dihydro-[1,3,4]oxadiazole-2-carboxylic acid ethyl ester | 61320-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-thioxo-4,5-dihydro-[1,3,4]oxadiazole-2-carboxylic acid ethyl ester
• 英文别名: 2-ethoxycarbonyl-1,3,4-oxadiazole-5-thiol；Ethyl 5-sulfanyl-1,3,4-oxadiazole-2-carboxylate；ethyl 2-sulfanylidene-3H-1,3,4-oxadiazole-5-carboxylate
• CAS: 61320-93-2
• 化学式: C₅H₆N₂O₃S
• 分子量: 174.18
• InChiKey: NEKIIXYWGLWRFP-UHFFFAOYSA-N

物化性质

• 沸点：
  204.3±23.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  92
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-thioxo-4,5-dihydro-[1,3,4]oxadiazole-2-carboxylic acid ethyl ester 在 氨 作用下， 生成 5-mercapto-1,3,4-oxadiazol-2-ylcarboxamide
  参考文献：
  名称：

  Cephalosporin derivatives

  摘要：

  已制备了一系列新型7-(D.α.-氨基苯乙酰胺基)-和7-(D.α.-羟基苯乙酰胺基)-Δ3-头孢菌素衍生物，其中杂环硫甲基基团位于分子的3位。这些化合物可用作抗菌剂，用于治疗由革兰氏阳性和革兰氏阴性细菌引起的疾病。首选成员包括7-(D.α.-羟基苯乙酰胺基)-3-(3-氨基甲酰-1,2,4-三唑-5-基)硫甲基头孢-3-酮-4-羧酸和7-(D.α.-羟基苯乙酰胺基)-3-(2-羧甲氧甲基-1,3,4-噻二唑-5-基)硫甲基头孢-3-酮-4-羧酸。提供了这些化合物的替代制备方法，包括导致所需新型杂环硫醇中间体的各种合成路线。

  公开号：

  US04080451A1
• 作为产物：
  描述：

  二硫化碳 、 草酸单乙酯酰肼 生成 5-thioxo-4,5-dihydro-[1,3,4]oxadiazole-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  Five-membered Heterocyclic Thiones. Part I. 1,3,4-Oxadiazole-2-thione

  摘要：

  1,3,4-噁二唑-2-硫酮是通过相应的5-羧酸的脱羧反应制备的。光谱数据支持在溶液中主要存在硫酮形式，如果不是唯一存在的话。

  DOI：

  10.1139/v72-489

文献信息

• New potent inhibitors of tyrosinase: Novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triazole-5(4H)-thiones, and substituted hydrazides to the dicopper active site
  作者：Usman Ghani、Nisar Ullah

  DOI：10.1016/j.bmc.2010.04.021

  日期：2010.6.1

  hydrazides were tailored and synthesized as new potent inhibitors of tyrosinase. The rationale for inhibitor design was based on the active site structural evidence from the crystal structures of bacterial tyrosinase and potato catechol oxidase enzymes. Kinetic and active site binding studies suggested mono-dentate binding of thiadiazole, oxadiazole, and triazole rings to the active site dicopper center

  一系列1,3,4-噻二唑-2（3 H）-硫酮，1,3,4-恶二唑-2（3 H）-硫酮，4-氨基-1,2,4-三唑-5（4）H）-硫酮和取代的酰肼被定制并合成为酪氨酸酶的新型有效抑制剂。设计抑制剂的基本原理是基于细菌酪氨酸酶和马铃薯儿茶酚氧化酶的晶体结构的活性位点结构证据。动力学和活性位点结合研究表明，噻二唑，恶二唑和三唑环与酪氨酸酶活性位点双铜中心的单齿结合包括疏水性，有助于有效抑制。动力学图显示了所有25种化合物的混合抑制类型。发现在对酪氨酸酶的高结合亲和力中，三唑环的C3取代和噻二唑/恶二唑环的C5取代起主要作用。
• 7-Aminophenylacetamido-.DELTA..sup.3 -cephem antibacterial agents and
  申请人：Pfizer Inc.

  公开号：US04183925A1

  公开（公告）日：1980-01-15

  A series of novel 7-(D-.alpha.-aminophenylacetamido)- and 7-(D-.alpha.-hydroxyphenylacetamido)-.DELTA..sup.3 -cephem derivatives have been prepared wherein a heterocyclic thiomethyl moiety is located at the 3-position of the molecule. These compounds are useful as antibacterial agents for the treatment of diseases caused by Gram-positive and Gram-negative bacteria. Preferred members include 7-(D-.alpha.-hydroxyphenylacetamido)-3-(3-carbamoyl-1,2,4-triazol-5-yl)thi omethylceph-3-em-4-carboxylic acid and 7-(D-.alpha.-hydroxyphenylacetamido)-3-(2-carboxymethoxy-methyl-1,3,4-thia diazol-5-yl)thiomethylceph-3-em-4-carboxylic acid. Alternative methods of preparation are provided for these compounds, including various synthetic routes leading to the required novel heterocyclic thiol intermediates.

  一系列新型7-(D-.alpha.-氨基苯乙酰胺基)-和7-(D-.alpha.-羟基苯乙酰胺基)-.DELTA..sup.3-头孢菌素衍生物已制备，其中杂环硫甲基基团位于分子的3-位置。这些化合物可用作治疗由革兰氏阳性和革兰氏阴性细菌引起的疾病的抗菌剂。首选成员包括7-(D-.alpha.-羟基苯乙酰胺基)-3-(3-氨基甲酰基-1,2,4-三唑-5-基)硫甲基头孢-3-酰基-4-羧酸和7-(D-.alpha.-羟基苯乙酰胺基)-3-(2-羧甲氧基甲基-1,3,4-噻二唑-5-基)硫甲基头孢-3-酰基-4-羧酸。提供了这些化合物的替代制备方法，包括导致所需新型杂环硫醇中间体的各种合成路线。
• Substituted mercaptothiadiazole compounds
  申请人：Pfizer Inc.

  公开号：US04144240A1

  公开（公告）日：1979-03-13

  A series of novel 7-(D-.alpha.-aminophenylacetamido)- and 7-(D-.alpha.-hydroxyphenylacetamido)-.DELTA..sup.3 -cephem derivatives have been prepared wherein a heterocyclic thiomethyl moiety is located at the 3-position of the molecule. These compounds are useful as antibacterial agents for the treatment of diseases caused by Gram-positive and Gram-negative bacteria. Preferred members include 7-(D-.alpha.-hydroxyphenylacetamido)-3-(3-carbamoyl-1,2,4-triazol-5-yl)thi omethylceph-3-em-4-carboxylic acid and 7-(D-.alpha.-hydroxyphenylacetamido)-3-(2-carboxymethoxy-methyl-1,3,4-thia diazol-5-yl)thiomethylceph-3-em-4-carboxylic acid. Alternative methods of preparation are provided for these compounds, including various synthetic routes leading to the required novel heterocyclic thiol intermediates.

  一系列新型的7-(D-.alpha.-氨基苯乙酰胺基)-和7-(D-.alpha.-羟基苯乙酰胺基)-.DELTA..sup.3-头孢菌素衍生物已被制备，其中杂环硫甲基基团位于分子的3位。这些化合物可用于治疗由革兰氏阳性和革兰氏阴性细菌引起的疾病的抗菌剂。首选成员包括7-(D-.alpha.-羟基苯乙酰胺基)-3-(3-氨基甲酰-1,2,4-三唑-5-基)硫甲基头孢-3-酮-4-羧酸和7-(D-.alpha.-羟基苯乙酰胺基)-3-(2-羧甲氧基甲基-1,3,4-噻二唑-5-基)硫甲基头孢-3-酮-4-羧酸。还提供了这些化合物的替代制备方法，包括导致所需新型杂环硫醇中间体的各种合成路线。
• Five-membered Heterocyclic Thiones. Part I. 1,3,4-Oxadiazole-2-thione
  作者：D. E. Horning、J. M. Muchowski

  DOI：10.1139/v72-489

  日期：1972.9.15

  1,3,4-Oxadiazole-2-thione was prepared by decarboxylation of the corresponding 5-carboxylic acid. Spectral data supported the predominant, if not exclusive, existence of the thione form in solution.

  1,3,4-噁二唑-2-硫酮是通过相应的5-羧酸的脱羧反应制备的。光谱数据支持在溶液中主要存在硫酮形式，如果不是唯一存在的话。
• Cephalosporin derivatives
  申请人：Pfizer Inc.

  公开号：US04080451A1

  公开（公告）日：1978-03-21

  A series of novel 7-(D.alpha.-aminophenylacetamido)- and 7-(D-.alpha.-hydroxyphenylacetamido)- .DELTA..sup.3 -cephem derivatives have been prepared wherein a heterocyclic thiomethyl moiety is located at the 3-position of the molecule. These compounds are useful as antibacterial agents for the treatment of diseases caused by Gram-positive and Gram-negative bacteria. Preferred members include 7-(D-.alpha.-hydroxyphenylacetamido)-3-(3-carbamoyl-1,2,4-triazol-5-yl)thi omethylceph-3-em-4-carboxylic acid and 7-(D-.alpha.-hydroxyphenylacetamido)-3-(2-carboxymethoxy-methyl-1,3,4-thia diazol-5-yl)thiomethylceph-3-em-4-carboxylic acid. Alternative methods of preparation are provided for these compounds, including various synthetic routes leading to the required novel heterocyclic thiol intermediates.

  已制备了一系列新型7-(D.α.-氨基苯乙酰胺基)-和7-(D.α.-羟基苯乙酰胺基)-Δ3-头孢菌素衍生物，其中杂环硫甲基基团位于分子的3位。这些化合物可用作抗菌剂，用于治疗由革兰氏阳性和革兰氏阴性细菌引起的疾病。首选成员包括7-(D.α.-羟基苯乙酰胺基)-3-(3-氨基甲酰-1,2,4-三唑-5-基)硫甲基头孢-3-酮-4-羧酸和7-(D.α.-羟基苯乙酰胺基)-3-(2-羧甲氧甲基-1,3,4-噻二唑-5-基)硫甲基头孢-3-酮-4-羧酸。提供了这些化合物的替代制备方法，包括导致所需新型杂环硫醇中间体的各种合成路线。